(2S)-N-(2-phenylethyl)pyrrolidine-2-carboxamide | 123729-66-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-(2-phenylethyl)pyrrolidine-2-carboxamide
• CAS: 123729-66-8
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: VMZJWMLESLZMMJ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S)-N-(2-phenylethyl)pyrrolidine-2-carboxamide 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity

  摘要：

  Signal transducer and activator of transcription 6 (STAT6) transmits signals from cytokines IL-4 and IL-13 and is activated in allergic airway disease. We are developing phosphopeptide mimetics targeting the SH2 domain of STAT6 to block recruitment to phosphotyrosine residues on IL-4 or IL-13 receptors and subsequent Tyr641 phosphorylation to inhibit the expression of genes contributing to asthma. Structure-affinity relationship studies showed that phosphopeptides based on Tyr631 from IL-4R alpha bind with weak affinity to STAT6, whereas replacing the pY+3 residue with simple aryl and alkyl amides resulted in affinities in the mid to low nM range. A set of phosphatase-stable, cell-permeable prodrug analogues inhibited cytokine-stimulated STAT6 phosphorylation in both Beas-2B human airway cells and primary mouse T-lymphocytes at concentrations as low as 100 nM. IL-13-stimulated expression of CCL26 (eotaxin-3) was inhibited in a dose-dependent manner, demonstrating that targeting the SH2 domain blocks both phosphorylation and transcriptional activity of STAT6.

  DOI：

  10.1021/acs.jmedchem.5b01321
• 作为产物：
  描述：

  benzyl (2S)-2-(2-phenylethylcarbamoyl)pyrrolidine-1-carboxylate 生成 (2S)-N-(2-phenylethyl)pyrrolidine-2-carboxamide
  参考文献：
  名称：

  KASAFIREK, EVZEN;SUTIAKOVA, IRENA;BARTIK, MICHAL;STURC, ANTONIN, COLLECT. CZECHOSL. CHEM. COMMUN., 53,(1988) N1B, C. 2877-2883

  摘要：

  DOI：

文献信息

• Synthesis and Catalytic Activities of (<i>S</i>)-1-formylpyrrolidine-2-carboxylic Acid Derivatives for the Enantioselective Reductions of Both a Ketone and a Ketimine
  作者：Zhenfei Chen、Anjiang Zhang、Lixue Zhang、Jing Zhang、Xinxiang Lei

  DOI：10.3184/030823408x318433

  日期：2008.5

  as chiral organocatalysts in the asymmetric reduction of both ketone 2 and ketimine 3. These organic activators afforded good to moderate enantioselectivities in the asymmetric reductions of both the ketone and the ketimine. Among them, organic activator 6h displayed the best efficiency, affording a 84% yield and 41% ee in the reduction of the ketone and 75% yield and 52% ee in the reduction of the ketimine

  一系列 (S)-1-甲酰基吡咯烷-2-羧酸衍生物 (6a-t) 已被合成并作为手性有机催化剂用于酮 2 和酮亚胺 3 的不对称还原。这些有机活化剂提供了良好到中等的对映选择性酮和酮亚胺的不对称还原。其中，有机活化剂6h显示出最佳的效率，在酮的还原中提供了84％的收率和41％的ee，在酮亚胺的还原中提供了75％的收率和52％的ee。
• [EN] ALKYNE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS ALCYNE POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035348A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is alkyne substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein can reduce the excessive activation of complement.

  提供了有关抑制补体因子D的化合物、使用方法和制备过程，包括公式I中的化合物，或其药用盐或组合物，其中A组上的R12或R13是炔基取代物（R32）。本文描述的抑制剂针对因子D并抑制或调节补体级联。本文描述的因子D的抑制剂可以减少补体的过度激活。
• Dolastatin 15 derivatives
  申请人：Janssen Bernd

  公开号：US20060270606A1

  公开（公告）日：2006-11-30

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G) r -(K) s -L   (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为式I中的肽，A-B-D-E-F-(G)r-(K)s-L，以及其酸盐，其中A、B、D、E、F、G和K是α-氨基酸残基，s和r各自独立地为0或1。L是单价基团，例如氨基、N-取代氨基、β-羟胺基、肼基、烷氧基、硫烷氧基、氨氧基或氧化肟基。本发明还包括一种用于治疗哺乳动物（例如人类）癌症的方法，包括向哺乳动物中给予式I化合物的有效量，以一种药学上可接受的组合物形式。
• DOLASTATIN 15 DERIVATIVES
  申请人：JANSSEN Bernd

  公开号：US20100099843A1

  公开（公告）日：2010-04-22

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G) r -(K) s -L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为公式I中的肽，A-B-D-E-F-(G)r-(K)s-L（I），以及其酸盐，其中A、B、D、E、F、G和K均为α-氨基酸残基，s和r各自独立地为0或1。L是单价基团，例如氨基、N-取代氨基、β-羟胺基、肼基、烷氧基、硫烷氧基、氨氧基或氧肟基等。本发明还包括一种治疗哺乳动物（例如人类）癌症的方法，包括向哺乳动物中以药学上可接受的组成物的有效量给予公式I的化合物。
• KASAFIREK, EVZEN;SUTIAKOVA, IRENA;BARTIK, MICHAL;STURC, ANTONIN, COLLECT. CZECHOSL. CHEM. COMMUN., 53,(1988) N1B, C. 2877-2883
  作者：KASAFIREK, EVZEN、SUTIAKOVA, IRENA、BARTIK, MICHAL、STURC, ANTONIN

  DOI：——

  日期：——